Objective. To assess the efficacy of apatinib plus S‐1 therapy in the treatment of advanced
gastric cancer patients and the effect on the levels of tumor markers and Th1 and Th2‐like …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKI)
acquired resistance was an inevitably events in NSCLC treatment. Aims Intending to …

Background Anlotinib and apatinib, both vascular endothelial growth factor receptor-tyrosine
kinase inhibitors (VEGFR-TKIs), are clinically established in the treatment of advanced non …

Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are
considered as the first-line treatment for advanced EGFR mutation-positive non-small cell …

Background: Although various effective compounds for the second-and third-line treatment
of advanced or recurrent cervical cancer improved the overall survival, the optimal regimen …

EGFR kinase domain duplication in lung adenocarcinoma with systemic and intracranial
response to a double-dose of furmonertinib: a case report and literature review - PMC Back to …

肺癌是最常见、 致死率最高的肿瘤性疾病之一， 使用表皮生长因子受体酪氨酸激酶抑制剂（
epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI） 已经成为EGFR …

Background The types of epidermal growth factor receptor (EGFR)–mutant non–small-cell
lung cancer (NSCLC) patients who could obtain significant clinical benefit from the dual …

Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR
mutations, the suggested course of action is epidermal growth factor receptor-tyrosine …

甲状腺未分化癌 (ATC) 是一种恶性程度高, 侵袭性强的甲状腺恶性肿瘤, 发病迅速, 预后差,
目前尚缺乏有效治疗手段. 分子靶向治疗为 ATC 治疗提供了一种新思路. 酪氨酸激酶抑制剂乐伐 …